Table 2 Procedural characteristics of TAVR patients
From: Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve replacement
Non-diabetic (N = 285) | Diabetic (N = 158) | P-value | ||
|---|---|---|---|---|
NIDDM (N = 114) | IDDM (N = 44) | |||
Approach | ||||
Trans-femoral | 209 (76) | 86 (79) | 31 (74) | 0.53 |
Trans-apical | 49 (18) | 19 (17) | 9 (21) | |
Other | 17 (6) | 3 (3) | 2 (5) | |
Anesthesia | ||||
General | 89 (39) | 34 (34) | 12 (36) | 0.55 |
Conscious sedation | 140 (61) | 66 (66) | 21 (61) | |
Valve type | ||||
SAPIEN XT | 109 (41) | 48 (45) | 18 (45) | 0.35 |
CoreValve | 159 (58) | 55 (51) | 20 (50) | |
Other | 5 (1) | 2 (2) | 0 (0) | |
Valve size | ||||
23 mm | 52 (20) | 19 (18) | 9 (24) | 0.77 |
25 mm | 0 (0) | 1 (1) | 0 (0) | |
26 mm | 106 (41) | 45 (44) | 13 (35) | |
29 mm | 93 (36) | 34 (33) | 13 (35) | |
31 mm | 6 (2) | 4 (4) | 2 (5) | |
Valve-in-valve | 25 (9) | 12 (11) | 8 (20) | 0.11 |
Procedural success | 262 (98) | 103 (97) | 38 (100) | 0.59 |
Pre procedural EF | 55 ± 12 | 56 ± 12 | 54 ± 12 | 0.48 |
Pre-procedural moderate to severe MR | 74 (26) | 26 (23) | 10 (23) | 0.76 |
Post-procedural moderate to severe AR | 37 (13) | 14 (12) | 2 (5) | 0.27 |